TY - JOUR AU - Biró, Orsolya AU - Alasztics, Bálint AU - Molvarec, Attila AU - Joó, József Gábor AU - Nagy, Bálint AU - Rigó, János TI - Various levels of circulating exosomal total-miRNA and miR-210 hypoxamiR in different forms of pregnancy hypertension JF - PREGNANCY HYPERTENSION J2 - PREGNANCY HYPERTENS VL - 10 PY - 2017 SP - 207 EP - 212 PG - 6 SN - 2210-7789 DO - 10.1016/j.preghy.2017.09.002 UR - https://m2.mtmt.hu/api/publication/3273020 ID - 3273020 AB - Introduction: Hypertension is a common complication during pregnancy, affecting 10% of pregnant women worldwide. Several microRNA (miRNA) were shown to be involved in hypertensive disorders of pregnancy. In preeclampsia (PE), placental dysfunction causes the enhanced release of extracellular vesicle-derived miRNAs. The hypoxia-sensitive hsa-mir-210 is the most common PE-associated miRNA, but its exosomal profile has not been investigated. Objectives: Our aims were to measure exosomal total-miRNA concentration and to perform expression analysis of circulating exosomal hsa-miR-210 in women affected by chronic hypertension (CHT) gestational hypertension (GHT) or PE. Materials and methods: We collected plasma samples from women with CHT, GHT, PE (moderate: mPE and severe: sPE) and from normotensive pregnancies. Exosomal miRNAs were extracted and miRNA concentration was measured. RT-PCR was carried out with hsa-miR-210-3p-specific primers and relative expression was calculated using the comparative Ct method. Results: The total-miRNA concentration was different in the disease subgroups, and was significantly higher in mPE and sPE compared to the other groups. We found a significant difference in the relative exosomal hsa-miR-210-3p expression between all hypertensive groups compared to the normotensive samples, but significant upregulation was only observed in case of mPE and sPE patients. Both the level of total-miRNA and hsa-miR-210 expression was higher in case of severe PE. Conclusions: The level of circulating exosomal total-miRNA and hsa-miR-210 was elevated in women with PE, and it was higher in the severe form. We showed that hsa-miR-210 is secreted via exosomes, which may have a role in the pathomechanism of the disease. © 2017 International Society for the Study of Hypertension in Pregnancy. LA - English DB - MTMT ER - TY - JOUR AU - Varga, Zoltán AU - Gyurko, I AU - Pálóczi, Krisztina AU - Buzás, Edit Irén AU - Horvath, I AU - Hegedűs, Nikolett AU - Máthé, Domokos AU - Szigeti, Krisztián TI - Radiolabeling of Extracellular Vesicles with (99m)Tc for Quantitative In Vivo Imaging Studies. JF - CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS J2 - CANCER BIOTHER RADIO VL - 31 PY - 2016 IS - 5 SP - 168 EP - 173 PG - 6 SN - 1084-9785 DO - 10.1089/cbr.2016.2009 UR - https://m2.mtmt.hu/api/publication/3092009 ID - 3092009 AB - The biodistribution of extracellular vesicles (EVs) is a fundamental question in the field of circulating biomarkers, which has recently gained attention. Despite the capabilities of nuclear imaging methods, such as single-photon emission computed tomography, radioisotope labeling of EVs and the use of the aforementioned methods for in vivo studies hardly can be found in the literature. In this article, the authors describe a novel method for the radioisotope labeling of erythrocyte-derived EVs using the (99m)Tc-tricarbonyl complex. Moreover, the capability of the developed labeling method for in vivo biodistribution studies is demonstrated in a mouse model. The authors found that the intravenously administered (99m)Tc-labeled EVs mostly accumulated in the liver and spleen. The in vivo stability of the labeled EVs was assessed by the comparison of the obtained biodistribution of EVs with that of the free (99m)Tc-tricarbonyl. According to the authors' data, only a minor fraction of the radioactive label became detached from the EVs. LA - English DB - MTMT ER - TY - JOUR AU - Momen-Heravi, F AU - Bala, S AU - Kodys, K AU - Szabó, Gyöngyi TI - Exosomes derived from alcohol-treated hepatocytes horizontally transfer liver specific miRNA-122 and sensitize monocytes to LPS JF - SCIENTIFIC REPORTS J2 - SCI REP VL - 5 PY - 2015 SN - 2045-2322 DO - 10.1038/srep09991 UR - https://m2.mtmt.hu/api/publication/3106717 ID - 3106717 N1 - Megjegyzés-24781124 N1 Funding Details: AA011576, NIH, National Institutes of Health N1 Funding Details: AA020744, NIH, National Institutes of Health N1 Funding Details: AA021907, NIH, National Institutes of Health Megjegyzés-25227971 Hiányzó Jelleg: 'JOUR\n\nArticle' Admin megjegyzés-25227971 tblcategory: (Category) ('JOUR\n\nArticle') #Jelleg AB - Hepatocyte damage and inflammation in monocytes/macrophages are central to the pathogenesis of alcoholic hepatitis (AH). MicroRNAs (miRNAs) regulate all of these processes. MiRNA-122 is abundantly expressed in hepatocytes while monocytes/macrophages have low levels. The role of exosomes in AH and possible cross talk between hepatocyte-derived exosomes and immune cells is not explored yet. Here, we show that the number of exosomes significantly increases in the sera of healthy individuals after alcohol binge drinking and in mice after binge or chronic alcohol consumption. Exosomes isolated from sera after alcohol consumption or from in vitro ethanol-treated hepatocytes contained miRNA-122. Exosomes derived from ethanol-treated Huh7.5 cells were taken up by the recipients THP1 monocytes and horizontally transferred a mature form of liver-specific miRNA-122. In vivo, liver mononuclear cells and Kupffer cells from alcohol-fed mice had increased miRNA-122 levels. In monocytes, miRNA-122 transferred via exosomes inhibited the HO-1 pathway and sensitized to LPS stimulation and increased levels of pro-inflammatory cytokines. Finally, inflammatory effects of exosomes from ethanol-treated hepatocytes were prevented by using RNA interference via exosome-mediated delivery of a miRNA-122 inhibitor. These results demonstrate that first, exosomes mediate communication between hepatocytes and monocytes/macrophages and second, hepatocyte-derived miRNA-122 can reprogram monocytes inducing sensitization to LPS. LA - English DB - MTMT ER - TY - JOUR AU - Yanez-Mo, M AU - Siljander, PR AU - Andreu, Z AU - Zavec, AB AU - Borras, FE AU - Buzás, Edit Irén AU - Buzás, Krisztina AU - Casal, E AU - Cappello, F AU - Carvalho, J AU - Colas, E AU - Cordeiro-da Silva, A AU - Fais, S AU - Falcon-Perez, JM AU - Ghobrial, IM AU - Giebel, B AU - Gimona, M AU - Graner, M AU - Gursel, I AU - Gursel, M AU - Heegaard, NH AU - Hendrix, A AU - Kierulf, P AU - Kokubun, K AU - Kosanovic, M AU - Kralj-Iglic, V AU - Kramer-Albers, EM AU - Laitinen, S AU - Lasser, C AU - Lener, T AU - Ligeti, Erzsébet AU - Line, A AU - Lipps, G AU - Llorente, A AU - Lotvall, J AU - Mancek-Keber, M AU - Marcilla, A AU - Mittelbrunn, M AU - Nazarenko, I AU - Nolte-'t, Hoen EN AU - Nyman, TA AU - O'Driscoll, L AU - Olivan, M AU - Oliveira, C AU - Pállinger, Éva AU - Del Portillo, HA AU - Reventos, J AU - Rigau, M AU - Rohde, E AU - Sammar, M AU - Sanchez-Madrid, F AU - Santarem, N AU - Schallmoser, K AU - Ostenfeld, MS AU - Stoorvogel, W AU - Stukelj, R AU - Van, der Grein SG AU - Vasconcelos, MH AU - Wauben, MH AU - De Wever, O TI - Biological properties of extracellular vesicles and their physiological functions JF - JOURNAL OF EXTRACELLULAR VESICLES J2 - J EXTRACELLULAR VESICL VL - 4 PY - 2015 PG - 60 SN - 2001-3078 DO - 10.3402/jev.v4.27066 UR - https://m2.mtmt.hu/api/publication/2930099 ID - 2930099 N1 - Yanez-Mo M and Siljander PR authors have contributed equally. The rest of the authors are listed in alphabetical order. Unidad de Investigación, Hospital Sta Cristina, Instituto de Investigaciones Sanitarias Princesa (IIS-IP), Madrid, Spain Departamento de Biología Molecular, UAM, Madrid, Spain Extracellular Vesicle Research, Division of Biochemistry and Biotechnology, Department of Biosciences, University of Helsinki, Helsinki, Finland Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland Laboratory for Molecular Biology and Nanobiotechnology, National Institute of Chemistry, Ljubljana, Slovenia IVECAT Group, 'Germans Trias i Pujol' Research Institute, Badalona, Spain Nephrology Service, 'Germans Trias i Pujol' University Hospital, Badalona, Spain Department of Genetics, Cell- and Immunobiology, Semmelweis University, Budapest, Hungary Biological Research Centre, Hungarian Academy of Sciences, Szeged, Hungary Faculty of Dentistry, University of Szeged, Szeged, Hungary Metabolomics Unit, CIC bioGUNE, CIBERehd, Bizkaia Technology Park, Derio, Spain Department of Experimental Biomedicine and Clinical Neuroscience, Human Anatomy Section, University of Palermo, Palermo, Italy Euro-Mediterranean Institute of Science and Technology, Palermo, Italy Instituto de Investigação e Inovação em Saú de, Universidade do Porto, Porto, Portugal Expression Regulation in Cancer, Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Porto, Portugal Research Unit in Biomedicine and Translational Oncology, Vall Hebron Institute of Research and Autonomous, University of Barcelona, Barcelona, Spain IBMC, Instituto de Biologia Molecular e Celular, Universidade do Porto, Porto, Portugal Department of Biological Sciences, Faculty of Pharmacy, University of Porto, Porto, Portugal Anti-Tumour Drugs Section, Department of Therapeutic Research and Medicines Evaluation, National Institute of Health (ISS), Rome, Italy IKERBASQUE, Basque Foundation for Science, Bilbao, Spain Dana-Farber Cancer Institute, Boston, MA, United States Institute for Transfusion Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany Spinal Cord Injury and Tissue Regeneration Center Salzburg (SCI-TReCS), Paracelsus Medical University (PMU), Salzburg, Austria Department of Blood Group Serology and Transfusion Medicine, Universitätsklinikum, Salzburger Landeskliniken GesmbH (SALK), Salzburg, Austria Department of Neurosurgery, University of Colorado DenverCO, United States Department of Molecular Biology and Genetics, Thorlab-Therapeutic Oligonucleotide Research Lab, Bilkent University, Ankara, Turkey Department of Biological Sciences, Middle East Technical University, Ankara, Turkey Department of Clinical Biochemistry and Pharmacology, Odense University Hospital, University of Southern Denmark, Odense, Denmark Analytical Protein Chemistry, Department of Clinical Biochemistry, Immunology and Genetics, Statens Serum Institut, Copenhagen, Denmark Laboratory of Experimental Cancer Research, Department of Radiation Oncology and Experimental Cancer Research, Ghent University Hospital, Ghent, Belgium Bood Cell Research Group, Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway Department of Immunochemistry and Glycobiology, Institute for the Application of Nuclear Energy, INEP, University of Belgrade, Belgrade, Serbia Laboratory of Clinical Biophysics, Faculty of Health Sciences, University of Ljubljana, Ljubljana, Slovenia Molecular Cell Biology and Focus Program Translational Neurosciences, University of Mainz, Mainz, Germany Research and Cell Services, Finnish Red Cross Blood Service, Helsinki, Finland Krefting Research Centre, Institute of Medicine at the Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden Department of Physiology, Semmelweis University, Budapest, Hungary Latvian Biomedical Research and Study Centre, Riga, Latvia Institute of Chemistry and Bioanalytics, School of Life Sciences, University of Applied Sciences and Arts Northwestern Switzerland, Muttenz, Switzerland Department of Molecular Cell Biology, Institute for Cancer Research, Oslo University Hospital - The Norwegian Radium Hospital, Oslo, Norway National Institute of Chemistry, Laboratory of Biotechnology, Ljubljana, Slovenia ENFIST Centre of Excellence, Ljubljana, Slovenia Departamento de Biología Celular y Parasitologia, Facultat de Farmacia, Universitat de Valencia, Valencia, Spain Department of Vascular Biology and Inflammation, Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain Institute for Environmental Health Sciences, Hospital Infection Control Medical Center, University of Freiburg, Freiburg im Breisgau, Germany Department of Biochemistry and Cell Biology, Faculty of Veterinary Medicine, Utrecht University, Utrecht, Netherlands Institute of Biotechnology, University of Helsinki, Viikinkaari 1, Helsinki, Finland School of Pharmacy and Pharmaceutical Sciences, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland Department of Pathology and Oncology, Faculty of Medicine, University of Porto, Porto, Portugal ISGlobal, Barcelona Ctr. Int. Health Res. (CRESIB), Hospital Clínic - Universitat de Barcelona, Barcelona, Spain Institució Catalana de Recerca I Estudis Avançats, Barcelona, Spain Departament de Ciències Bàsiques, Universitat Internacional de Catalunya, Institut de Recerca Biomèdica de Bellvitge, Barcelona, Spain Department of Biotechnology Engineering, ORT Braude College, Karmiel, Israel Servicio de Inmunología, Hospital de la Princesa, Instituto de Investigaciones Sanitarias Princesa (IIS-IP), Madrid, Spain Departmnet of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark Cancer Drug Resistance Group, Institute of Molecular Pathology and Immunology, University of Porto (IPATIMUP), Porto, Portugal Department of Biological Sciences, Faculty of Pharmacy, University of Porto (FFUP), Porto, Portugal Cited By :955 Export Date: 30 August 2019 Correspondence Address: Yáñez-Mó, M.; Membrane Microdomains in Immunity Laboratory, Unidad de Investigación, Hospital Santa Cristina, Instituto de Investigación Sanitaria Princesa, Departamento de Biología Molecular, UAM, C/Maestro Amadeo Vives 2, edificio consultas 5a planta, Spain Chemicals/CAS: DNA, 9007-49-2; lipid, 66455-18-3; RNA, 63231-63-0 Unidad de Investigación, Hospital Sta Cristina, Instituto de Investigaciones Sanitarias Princesa (IIS-IP), Madrid, Spain Departamento de Biología Molecular, UAM, Madrid, Spain Extracellular Vesicle Research, Division of Biochemistry and Biotechnology, Department of Biosciences, University of Helsinki, Helsinki, Finland Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland Laboratory for Molecular Biology and Nanobiotechnology, National Institute of Chemistry, Ljubljana, Slovenia IVECAT Group, 'Germans Trias i Pujol' Research Institute, Badalona, Spain Nephrology Service, 'Germans Trias i Pujol' University Hospital, Badalona, Spain Department of Genetics, Cell- and Immunobiology, Semmelweis University, Budapest, Hungary Biological Research Centre, Hungarian Academy of Sciences, Szeged, Hungary Faculty of Dentistry, University of Szeged, Szeged, Hungary Metabolomics Unit, CIC bioGUNE, CIBERehd, Bizkaia Technology Park, Derio, Spain Department of Experimental Biomedicine and Clinical Neuroscience, Human Anatomy Section, University of Palermo, Palermo, Italy Euro-Mediterranean Institute of Science and Technology, Palermo, Italy Instituto de Investigação e Inovação em Saú de, Universidade do Porto, Porto, Portugal Expression Regulation in Cancer, Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Porto, Portugal Research Unit in Biomedicine and Translational Oncology, Vall Hebron Institute of Research and Autonomous, University of Barcelona, Barcelona, Spain IBMC, Instituto de Biologia Molecular e Celular, Universidade do Porto, Porto, Portugal Department of Biological Sciences, Faculty of Pharmacy, University of Porto, Porto, Portugal Anti-Tumour Drugs Section, Department of Therapeutic Research and Medicines Evaluation, National Institute of Health (ISS), Rome, Italy IKERBASQUE, Basque Foundation for Science, Bilbao, Spain Dana-Farber Cancer Institute, Boston, MA, United States Institute for Transfusion Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany Spinal Cord Injury and Tissue Regeneration Center Salzburg (SCI-TReCS), Paracelsus Medical University (PMU), Salzburg, Austria Department of Blood Group Serology and Transfusion Medicine, Universitätsklinikum, Salzburger Landeskliniken GesmbH (SALK), Salzburg, Austria Department of Neurosurgery, University of Colorado DenverCO, United States Department of Molecular Biology and Genetics, Thorlab-Therapeutic Oligonucleotide Research Lab, Bilkent University, Ankara, Turkey Department of Biological Sciences, Middle East Technical University, Ankara, Turkey Department of Clinical Biochemistry and Pharmacology, Odense University Hospital, University of Southern Denmark, Odense, Denmark Analytical Protein Chemistry, Department of Clinical Biochemistry, Immunology and Genetics, Statens Serum Institut, Copenhagen, Denmark Laboratory of Experimental Cancer Research, Department of Radiation Oncology and Experimental Cancer Research, Ghent University Hospital, Ghent, Belgium Bood Cell Research Group, Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway Department of Immunochemistry and Glycobiology, Institute for the Application of Nuclear Energy, INEP, University of Belgrade, Belgrade, Serbia Laboratory of Clinical Biophysics, Faculty of Health Sciences, University of Ljubljana, Ljubljana, Slovenia Molecular Cell Biology and Focus Program Translational Neurosciences, University of Mainz, Mainz, Germany Research and Cell Services, Finnish Red Cross Blood Service, Helsinki, Finland Krefting Research Centre, Institute of Medicine at the Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden Department of Physiology, Semmelweis University, Budapest, Hungary Latvian Biomedical Research and Study Centre, Riga, Latvia Institute of Chemistry and Bioanalytics, School of Life Sciences, University of Applied Sciences and Arts Northwestern Switzerland, Muttenz, Switzerland Department of Molecular Cell Biology, Institute for Cancer Research, Oslo University Hospital - The Norwegian Radium Hospital, Oslo, Norway National Institute of Chemistry, Laboratory of Biotechnology, Ljubljana, Slovenia ENFIST Centre of Excellence, Ljubljana, Slovenia Departamento de Biología Celular y Parasitologia, Facultat de Farmacia, Universitat de Valencia, Valencia, Spain Department of Vascular Biology and Inflammation, Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain Institute for Environmental Health Sciences, Hospital Infection Control Medical Center, University of Freiburg, Freiburg im Breisgau, Germany Department of Biochemistry and Cell Biology, Faculty of Veterinary Medicine, Utrecht University, Utrecht, Netherlands Institute of Biotechnology, University of Helsinki, Viikinkaari 1, Helsinki, Finland School of Pharmacy and Pharmaceutical Sciences, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland Department of Pathology and Oncology, Faculty of Medicine, University of Porto, Porto, Portugal ISGlobal, Barcelona Ctr. Int. Health Res. (CRESIB), Hospital Clínic - Universitat de Barcelona, Barcelona, Spain Institució Catalana de Recerca I Estudis Avançats, Barcelona, Spain Departament de Ciències Bàsiques, Universitat Internacional de Catalunya, Institut de Recerca Biomèdica de Bellvitge, Barcelona, Spain Department of Biotechnology Engineering, ORT Braude College, Karmiel, Israel Servicio de Inmunología, Hospital de la Princesa, Instituto de Investigaciones Sanitarias Princesa (IIS-IP), Madrid, Spain Departmnet of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark Cancer Drug Resistance Group, Institute of Molecular Pathology and Immunology, University of Porto (IPATIMUP), Porto, Portugal Department of Biological Sciences, Faculty of Pharmacy, University of Porto (FFUP), Porto, Portugal Cited By :1100 Export Date: 14 January 2020 Correspondence Address: Yáñez-Mó, M.; Membrane Microdomains in Immunity Laboratory, Unidad de Investigación, Hospital Santa Cristina, Instituto de Investigación Sanitaria Princesa, Departamento de Biología Molecular, UAM, C/Maestro Amadeo Vives 2, edificio consultas 5a planta, Spain Chemicals/CAS: DNA, 9007-49-2; lipid, 66455-18-3; RNA, 63231-63-0 Funding Agency and Grant Number: European Network on Microvesicles and Exosomes in Health & Disease (ME-HaD) [BM1202]; ICREAICREA Funding text: The authors wish to thank Dr R Simpson and Dr D Taylor for critical reading of the manuscript and acknowledge the Horizon 2020 European Cooperation in Science and Technology programme and its support of our European Network on Microvesicles and Exosomes in Health & Disease (ME-HaD; BM1202 www.cost.eu/COST_Actions/bmbs/Actions/BM1202) Unidad de Investigación, Hospital Sta Cristina, Instituto de Investigaciones Sanitarias Princesa (IIS-IP), Madrid, Spain Departamento de Biología Molecular, UAM, Madrid, Spain Extracellular Vesicle Research, Division of Biochemistry and Biotechnology, Department of Biosciences, University of Helsinki, Helsinki, Finland Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland Laboratory for Molecular Biology and Nanobiotechnology, National Institute of Chemistry, Ljubljana, Slovenia IVECAT Group, 'Germans Trias i Pujol' Research Institute, Badalona, Spain Nephrology Service, 'Germans Trias i Pujol' University Hospital, Badalona, Spain Department of Genetics, Cell- and Immunobiology, Semmelweis University, Budapest, Hungary Biological Research Centre, Hungarian Academy of Sciences, Szeged, Hungary Faculty of Dentistry, University of Szeged, Szeged, Hungary Metabolomics Unit, CIC bioGUNE, CIBERehd, Bizkaia Technology Park, Derio, Spain Department of Experimental Biomedicine and Clinical Neuroscience, Human Anatomy Section, University of Palermo, Palermo, Italy Euro-Mediterranean Institute of Science and Technology, Palermo, Italy Instituto de Investigação e Inovação em Saú de, Universidade do Porto, Porto, Portugal Expression Regulation in Cancer, Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Porto, Portugal Research Unit in Biomedicine and Translational Oncology, Vall Hebron Institute of Research and Autonomous, University of Barcelona, Barcelona, Spain IBMC, Instituto de Biologia Molecular e Celular, Universidade do Porto, Porto, Portugal Department of Biological Sciences, Faculty of Pharmacy, University of Porto, Porto, Portugal Anti-Tumour Drugs Section, Department of Therapeutic Research and Medicines Evaluation, National Institute of Health (ISS), Rome, Italy IKERBASQUE, Basque Foundation for Science, Bilbao, Spain Dana-Farber Cancer Institute, Boston, MA, United States Institute for Transfusion Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany Spinal Cord Injury and Tissue Regeneration Center Salzburg (SCI-TReCS), Paracelsus Medical University (PMU), Salzburg, Austria Department of Blood Group Serology and Transfusion Medicine, Universitätsklinikum, Salzburger Landeskliniken GesmbH (SALK), Salzburg, Austria Department of Neurosurgery, University of Colorado DenverCO, United States Department of Molecular Biology and Genetics, Thorlab-Therapeutic Oligonucleotide Research Lab, Bilkent University, Ankara, Turkey Department of Biological Sciences, Middle East Technical University, Ankara, Turkey Department of Clinical Biochemistry and Pharmacology, Odense University Hospital, University of Southern Denmark, Odense, Denmark Analytical Protein Chemistry, Department of Clinical Biochemistry, Immunology and Genetics, Statens Serum Institut, Copenhagen, Denmark Laboratory of Experimental Cancer Research, Department of Radiation Oncology and Experimental Cancer Research, Ghent University Hospital, Ghent, Belgium Bood Cell Research Group, Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway Department of Immunochemistry and Glycobiology, Institute for the Application of Nuclear Energy, INEP, University of Belgrade, Belgrade, Serbia Laboratory of Clinical Biophysics, Faculty of Health Sciences, University of Ljubljana, Ljubljana, Slovenia Molecular Cell Biology and Focus Program Translational Neurosciences, University of Mainz, Mainz, Germany Research and Cell Services, Finnish Red Cross Blood Service, Helsinki, Finland Krefting Research Centre, Institute of Medicine at the Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden Department of Physiology, Semmelweis University, Budapest, Hungary Latvian Biomedical Research and Study Centre, Riga, Latvia Institute of Chemistry and Bioanalytics, School of Life Sciences, University of Applied Sciences and Arts Northwestern Switzerland, Muttenz, Switzerland Department of Molecular Cell Biology, Institute for Cancer Research, Oslo University Hospital - The Norwegian Radium Hospital, Oslo, Norway National Institute of Chemistry, Laboratory of Biotechnology, Ljubljana, Slovenia ENFIST Centre of Excellence, Ljubljana, Slovenia Departamento de Biología Celular y Parasitologia, Facultat de Farmacia, Universitat de Valencia, Valencia, Spain Department of Vascular Biology and Inflammation, Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain Institute for Environmental Health Sciences, Hospital Infection Control Medical Center, University of Freiburg, Freiburg im Breisgau, Germany Department of Biochemistry and Cell Biology, Faculty of Veterinary Medicine, Utrecht University, Utrecht, Netherlands Institute of Biotechnology, University of Helsinki, Viikinkaari 1, Helsinki, Finland School of Pharmacy and Pharmaceutical Sciences, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland Department of Pathology and Oncology, Faculty of Medicine, University of Porto, Porto, Portugal ISGlobal, Barcelona Ctr. Int. Health Res. (CRESIB), Hospital Clínic - Universitat de Barcelona, Barcelona, Spain Institució Catalana de Recerca I Estudis Avançats, Barcelona, Spain Departament de Ciències Bàsiques, Universitat Internacional de Catalunya, Institut de Recerca Biomèdica de Bellvitge, Barcelona, Spain Department of Biotechnology Engineering, ORT Braude College, Karmiel, Israel Servicio de Inmunología, Hospital de la Princesa, Instituto de Investigaciones Sanitarias Princesa (IIS-IP), Madrid, Spain Departmnet of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark Cancer Drug Resistance Group, Institute of Molecular Pathology and Immunology, University of Porto (IPATIMUP), Porto, Portugal Department of Biological Sciences, Faculty of Pharmacy, University of Porto (FFUP), Porto, Portugal Cited By :1581 Export Date: 13 January 2021 Correspondence Address: Yáñez-Mó, M.; Membrane Microdomains in Immunity Laboratory, Unidad de Investigación, Hospital Santa Cristina, Instituto de Investigación Sanitaria Princesa, Departamento de Biología Molecular, UAM, C/Maestro Amadeo Vives 2, edificio consultas 5a planta, Spain Chemicals/CAS: DNA, 9007-49-2; lipid, 66455-18-3; RNA, 63231-63-0 Funding Agency and Grant Number: European Network on Microvesicles and Exosomes in Health & Disease (ME-HaD) [BM1202]; ICREAICREA Funding Source: Custom Funding text: The authors wish to thank Dr R Simpson and Dr D Taylor for critical reading of the manuscript and acknowledge the Horizon 2020 European Cooperation in Science and Technology programme and its support of our European Network on Microvesicles and Exosomes in Health & Disease (ME-HaD; BM1202 www.cost.eu/COST_Actions/bmbs/Actions/BM1202) AB - In the past decade, extracellular vesicles (EVs) have been recognized as potent vehicles of intercellular communication, both in prokaryotes and eukaryotes. This is due to their capacity to transfer proteins, lipids and nucleic acids, thereby influencing various physiological and pathological functions of both recipient and parent cells. While intensive investigation has targeted the role of EVs in different pathological processes, for example, in cancer and autoimmune diseases, the EV-mediated maintenance of homeostasis and the regulation of physiological functions have remained less explored. Here, we provide a comprehensive overview of the current understanding of the physiological roles of EVs, which has been written by crowd-sourcing, drawing on the unique EV expertise of academia-based scientists, clinicians and industry based in 27 European countries, the United States and Australia. This review is intended to be of relevance to both researchers already working on EV biology and to newcomers who will encounter this universal cell biological system. Therefore, here we address the molecular contents and functions of EVs in various tissues and body fluids from cell systems to organs. We also review the physiological mechanisms of EVs in bacteria, lower eukaryotes and plants to highlight the functional uniformity of this emerging communication system. LA - English DB - MTMT ER - TY - JOUR AU - Buzás, Edit Irén AU - György, Bence AU - Nagy, György AU - Falus, András AU - Gay, Steffen TI - Emerging role of extracellular vesicles in inflammatory diseases JF - NATURE REVIEWS RHEUMATOLOGY J2 - NAT REV RHEUMATOL VL - 10 PY - 2014 IS - 6 SP - 356 EP - 364 PG - 9 SN - 1759-4790 DO - 10.1038/nrrheum.2014.19 UR - https://m2.mtmt.hu/api/publication/2516546 ID - 2516546 LA - English DB - MTMT ER -